



Nonmalignant Hematology

Specialized in delivery of complex trial designs
and specific patient population challenges
for major and rare hematological conditions

In clinical research, the field of nonmalignant hematology is one of the most highly specialized—encompassing many different disorders from congenital and acquired bleeding disorders to anemias of very different origins. This therapeutic area often involves fierce competition for patients, complex trial designs and specific patient population challenges.



Our dedicated Syneos Health Nonmalignant Hematology team consists of global staff from all levels of management and operations. The team’s deep therapeutic area expertise equips us to build long and enduring site relationships, giving you unparalleled access to patient populations and their caregivers in an extensive range of major and rare hematological conditions.

Our therapeutic expertise in hematology and oncology runs deep and wide. Our unique lab-to-life service offering extends from preclinical and translational science to clinical development, regulatory and commercialization/marketing capabilities.

“Our therapeutic expertise in hematology and oncology runs deep and wide.”

How We Help You Succeed in Nonmalignant Hematology Studies

Developing treatments for patients with hematologic conditions requires an unusually high level of scientific expertise. For example:

- Assessing an investigational treatment’s efficacy, compared to current practices using intricate endpoints, demands in-depth experience and specific therapeutic knowledge
- Many nonmalignant hematological disorders are also rare and require deep, specialist understanding to address the needs of small patient populations
- Many nonmalignant hematology disorders are monogenic in origin and are ideal targets for gene therapy and other advanced therapies that require specialized operational team experience

We Are Therapeutically Aligned and Highly Specialized


Our Nonmalignant Hematology team is focused solely on this therapeutic area and works closely with other leading specialists, including key opinion leaders from across the globe, to offer exceptional depth and breadth of clinical development experience.

From our clinical research associates at sites to project managers and senior leadership, each of us is deeply committed to the field and understands its therapeutic nuances. Advanced therapy medicinal products and gene therapies are increasingly at the forefront of novel approaches in this setting and we understand the many ways that regulatory pathways to approval tend to be very different from those in other areas of clinical research.

Our total nonmalignant hematology experience spans 59 studies at approximately 2,000 sites worldwide involving over 4,500 patients. Our global team provides support and specialist staff in over 100 countries.



Nonmalignant Hematology Experience: All Phases
(Number of Trials)



“From our clinical research associates at sites to project managers and senior leadership, each of us is deeply committed to the field and understands its therapeutic nuances.”

* Indication was broadly defined and not otherwise specified in the protocol.

** Broad grouping of various discrete types of non-malignant hematology indications. Grouping made for summary and presentation purposes only. All experience data: 2016-2021. Data is representative of all Syneos Health company experience. Does not include non-interventional or healthy volunteers studies.

We Identify the Right Patients for Your Study and Have the Strong Relationships With the Sites You Need

Our site relationships are second to none. Our therapeutic alignment means that we are able to engage with focus, passion and peer-to-peer scientific expertise to develop deep relationships with key opinion leaders, investigators and sites. We are the only Clinical Research Organization (CRO) to field dedicated Medical Site Liaisons (MSLs) for this purpose.

Recruiting patients with nonmalignant hematologic conditions requires a deep understanding of their motivations. Some are concerned about the lifestyle impact of a new drug, while others seek trials based on potency and are prepared to endure potential side effects. We listen to and learn from patients every day.

We have the experience and resources to deliver robust patient identification strategies in an increasingly competitive landscape and to identify rare and, frequently, regional footprints to be where the patients are.

We maintain a range of specialty population databases to ensure that targeted patient populations can be evaluated against study inclusion/exclusion criteria; these are updated continuously so that we can “go where the patients are” and evaluate which sites are ready for your trials. Our exceptionally close working relationships with sites means we can ensure they follow your protocol consistently.

The number of patients with nonmalignant hematology conditions is small, so in an increasingly competitive landscape we go big on communication. Through our **Rare Disease Consortium**, we foster collaborative relationships between sites, physicians, patient advocacy groups, academic thought leaders and sponsors to support clinical development strategies that are tailored to specific rare diseases and focused on the needs of these special patients to facilitate their participation in clinical trials.

“We have the experience and resources to deliver robust patient identification strategies in an increasingly competitive landscape and identify rare and, frequently, regional footprints to be where the patients are.”



Our Operational Excellence Promotes Speed and Quality in Clinical Trial Execution

Our specialization in nonmalignant hematology means that we anticipate and proactively solve for important issues that can be overlooked in study design and execution, such as the scarcity of rare disease patients, difficulties in biological and targeted therapy development, similar project competition, trial design complexity/technicality and novel mechanisms of action.

Every Syneos Health trial is conducted using our Trusted Process®—a proven, metrics-driven system that standardizes clinical development for predictable study execution and operational excellence.

We believe that when everyone involved in getting new therapies to patients works together as one and toward the same goal, the likelihood of success increases exponentially.

“We believe that when everyone involved in getting new therapies to patients works together as one and toward the same goal, the likelihood of success increases exponentially.”

Whether motivated by the personal journey of a cancer patient or the challenge and rigor of cancer clinical research, we at Syneos Health® are passionate about collaborating for a cure.



Targeted Therapies



Novel and Emerging Therapies



Immuno-Oncology



About Syneos Health

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 27,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers' delivery of important therapies to patients. To learn more about how we are **Shortening the distance from lab to life**®, visit syneoshealth.com or [subscribe to our podcast](#).

Contact us

+1 919 876 9300
syneoshealth.com